Cargando…

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial

Background. Elderly persons often experience a reduced immune response to influenza vaccination. We evaluated the usual dose of AS03(A)-adjuvanted H5N1 pandemic vaccine (3.75 μg hemagglutinin of A/Vietnam/1194/2004-like strain) compared with a double dose in an elderly population. Methods. This phas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heijmans, Stéphane, De Meulemeester, Marc, Reynders, Paul, Giet, Didier, Demanet, Etienne, Devresse, Pierre-Yves, Icardi, Giancarlo, Dramé, Mamadou, Roman, François, Gillard, Paul
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2011
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068020/ https://www.ncbi.nlm.nih.gov/pubmed/21450995 http://dx.doi.org/10.1093/infdis/jiq174

Ejemplares similares

Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study
por: Gillard, Paul, et al.
Publicado: (2014)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
por: Gillard, Paul, et al.
Publicado: (2012)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice
por: Nachbagauer, Raffael, et al.
Publicado: (2016)

AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets
por: Stadlbauer, Daniel, et al.
Publicado: (2021)

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study
por: Nazareth, Irwin, et al.
Publicado: (2013)

Long-term booster schedules with AS03(A)-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
por: Gillard, Paul, et al.
Publicado: (2014)

Structural monitoring of a transient intermediate in the hemagglutinin fusion machinery on influenza virions
por: Benhaim, M. A., et al.
Publicado: (2020)

Acantholytic Pityriasis Rubra Pilaris Associated with Imiquimod 3.75% Application
por: Atanaskova Mesinkovska, Natasha, et al.
Publicado: (2011)

Case of large lentigo maligna melanoma of the scalp treated with 5% and 3.75% Imiquimod()()
por: Rovesti, Miriam, et al.
Publicado: (2021)

A single-dose, randomized, open-labeled, parallel-group study comparing the pharmacokinetics, pharmacodynamics and safety of leuprolide acetate microspheres 3.75 mg and Enantone(®) 3.75 mg in healthy male subjects
por: Hu, Xingjiang, et al.
Publicado: (2022)

Safety and immunogenicity of AS03(B) adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
por: Waddington, Claire S, et al.
Publicado: (2010)

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial
por: Schuind, Anne, et al.
Publicado: (2015)

Bis[4-(dimethylamino)pyridinium] 3.75-bromido-0.25-chloridodiphenylplumbate(IV)
por: Lo, Kong Mun, et al.
Publicado: (2008)

Complete response of locally advanced cutaneous squamous cell carcinoma of the eyelid to topical imiquimod 3.75%
por: Toso, Francesco, et al.
Publicado: (2022)

Improved Bunch Splitting for the 75ns LHC Beam
por: Damerau, H, et al.
Publicado: (2011)

Run 575 MD - 75.03.10: Vacuum experiment in Sector 21
por: Fischer, E
Publicado: (1975)

GNU Make: a program for directing recompilation : edition 0.50 for Make version 3.75 beta
por: Stallman, Richard M, et al.
Publicado: (1996)

Profile of clindamycin phosphate 1.2%/benzoyl peroxide 3.75% aqueous gel for the treatment of acne vulgaris
por: Nguyen, Tuyet A, et al.
Publicado: (2015)

Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis
por: Nisticò, Steven, et al.
Publicado: (2018)

Case of giant vulvar condyloma acuminata successfully treated with imiquimod 3.75% cream: A case report
por: Hum, Matthew, et al.
Publicado: (2018)

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2008)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Run 651, 75-11-03, 26 GeV, Clearing current measurement
por: Gröbner, Oswald, et al.
Publicado: (1975)

Imiquimod 3.75% for field‐directed therapy of actinic keratosis: results of a prospective case‐series study in Greece
por: Befon, Angeliki, et al.
Publicado: (2019)

Usefulness of Topical Imiquimod 3.75% in Cytokeratin 7 Positive Extramammary Paget Disease of the Vulva: Towards Personalized Therapy
por: Mazzilli, Sara, et al.
Publicado: (2021)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Extended study of photon stimulated gas desorption from OFHC copper by 3.75 keV critical energy photons
por: Gröbner, Oswald, et al.
Publicado: (1992)

Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age
por: Nolan, Terry, et al.
Publicado: (2014)

OR07-03 Continuous Subcutaneous Delivery of RhPTH(1-84) by Pump in Adults with Hypoparathyroidism
por: Bove-Fenderson, Erin, et al.
Publicado: (2020)

Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses
por: Puente-Massaguer, Eduard, et al.
Publicado: (2023)

H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
por: Moris, Philippe, et al.
Publicado: (2010)

531 Split-virion compared to Subunit Influenza Trivalent Influenza Vaccines Has Greater Effectiveness in Older Adults
por: Talbot, H. Keipp, et al.
Publicado: (2014)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Mechanism of HIV-1 Virion Entrapment by Tetherin
por: Venkatesh, Siddarth, et al.
Publicado: (2013)

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
por: Kim, You Jin, et al.
Publicado: (2013)

Effect of triptorelin 3.75 mg subcutaneously injection every 6 weeks on adult height in girls with idiopathic central precocious puberty
por: Liang, Yan, et al.
Publicado: (2015)

Comparison of three different diffractıve multifocal intraocular lenses with a +2.5, +3.0, and +3.75 diopter additıon power
por: Altinkurt, Emre, et al.
Publicado: (2019)

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea
por: Choi, Won Suk, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p317gevl0uribftgs930jah6jv